Patents Assigned to The University of Sheffield
-
Publication number: 20250099486Abstract: The invention provides a D-deoxyribose sugar for use in promoting wound healing wherein the sugar is provided in a carrier and wherein the carrier is a biocompatible matrix material or a hydrogel.Type: ApplicationFiled: December 11, 2024Publication date: March 27, 2025Applicants: The University of Sheffield, COMSATS Institute of Information TechnologyInventors: Muhammad Yar, Sheila MacNeil
-
Publication number: 20250025474Abstract: The invention provides a D-deoxyribose sugar for use in promoting wound healing wherein the sugar is provided in a carrier and wherein the carrier is a biocompatible matrix material or a hydrogel.Type: ApplicationFiled: February 23, 2024Publication date: January 23, 2025Applicants: The University of Sheffield, COMSATS Institute of Information TechnologyInventors: Muhammad Yar, Sheila MacNeil
-
Publication number: 20240241128Abstract: Provided herein are methods for determining the chance of a tumor not responding to an anti-cancer therapy (e.g., a T cell-based immunotherapy) based on the presence, density, number, and/or location of certain three-cell structures as described herein. The three-cell structures may comprise a T cell, an immunosuppressive tumor-associated macrophage, and an immunosuppressive regulatory T cell. Such methods may be useful for identifying patients not likely to respond to T cell-based immunotherapy. Also provided herein are methods for determining the prognosis and/or invasiveness of a tumor. The present disclosure also encompasses methods for treating a tumor, as well as kits for performing the methods disclosed herein.Type: ApplicationFiled: April 8, 2022Publication date: July 18, 2024Applicants: NeoGenomics Laboratories, Inc., The University of SheffieldInventors: Claire Lewis, Anna Juncker-Jensen, Mate Levente, Nicholas Matthew Stavrou, Mohammed Ridha Moamin, Richard Allen
-
Patent number: 11964944Abstract: Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.Type: GrantFiled: June 2, 2022Date of Patent: April 23, 2024Assignees: The University of Chicago, J. Craig Venter Institute, Inc., The University of Sheffield, Institute for Systems Biology, The University of Leeds, The University of Strathclyde, The Government of the United StatesInventors: Rima McLeod, Martin McPhillie, Colin W. G. Fishwick, Hernan Alejandro Lorenzi, Kai Wang, Taek-Kyun Kim, Yong Zhou, Leroy E. Hood, Ying Zhou, Kamal El Bissati, Mark Hickman, QiGui Li, Craig Roberts
-
Patent number: 11612626Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.Type: GrantFiled: February 13, 2020Date of Patent: March 28, 2023Assignees: Virttu Biologics Limited, The University of SheffieldInventors: Joe Conner, Munitta Muthana, Claire Elizabeth Lewis
-
Patent number: 11535859Abstract: The present invention relates to the modification of gene expression in plants in order to manipulate stomatal number, in particular to the modification of expression in plants of epidermal patterning factor (EPF). The invention also relates to genetically modified plants or plant parts with altered stomatal patterning compared to corresponding wild type plants or plant parts, where the plant stomatal development is altered by modification of the expression of EPF.Type: GrantFiled: April 26, 2018Date of Patent: December 27, 2022Assignee: The University of SheffieldInventors: Julie Elizabeth Gray, Lee Hunt, William Paul Quick
-
Patent number: 11400081Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.Type: GrantFiled: May 16, 2018Date of Patent: August 2, 2022Assignee: The University of SheffieldInventors: Gareth Richards, Timothy M. Skerry, Joseph P. A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
-
Patent number: 11345064Abstract: A method for removing a hollow support element (17) from within a moulded part (15) to form a cavity (25) within the moulded part, the hollow support element being disposed within the moulded part and composed of material having a softening temperature, the method comprising: heating a liquid (20) to a temperature at least equal to the softening temperature of the material; injecting the heated liquid into an opening (24) in the moulded part to deform the material; and removing deformed material and liquid from the cavity.Type: GrantFiled: April 20, 2018Date of Patent: May 31, 2022Assignees: McLaren Automotive Limited, The University of SheffieldInventors: Claudio Santoni, Elaine Arnold, Timothy Swait, Mark Laycock
-
Patent number: 11345945Abstract: The present invention provides a polypeptide comprising an N-terminal polypeptide domain having luciferase activity and a C-terminal polypeptide domain having VAMP1, VAMP2 or VAMP3 activity where VAMP stands for vesicle-associated membrane protein. Corresponding nucleic acid molecules, expression vectors and genetically modified cells are also provided. The invention also provides methods and uses of the same.Type: GrantFiled: February 14, 2018Date of Patent: May 31, 2022Assignee: The University Of SheffieldInventors: Bazbek Davletov, Andrew Alexander Peden, Aleksander Mikael Rudolf Rust, Ciara Louise Doran
-
Patent number: 10844351Abstract: This invention relates to an improved method for generating otic progenitor cells. The invention also relates to uses of such otic progenitor cells, for example as a medicament (e.g. in the treatment of hearing loss, deafness or other auditory disorder associated with loss of inner ear function) and/or in drug screening methods.Type: GrantFiled: March 30, 2016Date of Patent: November 24, 2020Assignee: The University of SheffieldInventors: Carlos Marcelo Nicolas Rivolta, Darrell Michael Barrott
-
Publication number: 20200289590Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.Type: ApplicationFiled: February 13, 2020Publication date: September 17, 2020Applicants: Virttu Biologics Limited, The University of SheffieldInventors: Joe Conner, Munitta Muthana, Claire Elizabeth Lewis
-
Patent number: 10717095Abstract: An end effector for a robot having a threaded shaft; a motor coupled to the shaft and configured to rotate the shaft about its axis; a nut threaded onto the shaft; a feature for preventing the nut from rotating about the axis of the shaft; and an elongate member fixed at one end to the nut and extending from the nut in a direction parallel to the axis of the shaft. The end effector may further include a container for containing a fluid having an elongate body portion having an opening at one end; and a reciprocable plunger extending into an opposite end of the body portion. A second end of the elongate member may be coupled to the plunger.Type: GrantFiled: February 2, 2017Date of Patent: July 21, 2020Assignees: BAE Systems plc, The University of SheffieldInventors: Martin Knott, Ryan Wesley Diver
-
Publication number: 20200160706Abstract: Examples relate to detectors for determining motion from visual cues, said determining being invariant to changes in at least one of temporal and spatial frequencies of said visual cues.Type: ApplicationFiled: May 8, 2018Publication date: May 21, 2020Applicant: The University of SheffieldInventor: Alex COPE
-
Patent number: 10596210Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.Type: GrantFiled: March 11, 2016Date of Patent: March 24, 2020Assignees: Virttu Biologics, The university of SheffieldInventors: Joe Conner, Munitta Muthana, Claire Elizabeth Lewis
-
Publication number: 20190204159Abstract: A thermal imaging device is provided, comprising: a detector for receiving radiation and outputting a detector signal corresponding thereto; a steerable mirror device arranged in relation to the detector; wherein the steerable mirror device is steerable to scan an entrance pupil over a plurality of locations such that the detector outputs respective detector signals indicative of temperatures of respective portions of the object corresponding to the locations of the entrance pupil, and wherein the thermal imaging device is configured to provide a substantially constant etendue for all of the entrance pupil locations of the plurality of entrance pupil locations.Type: ApplicationFiled: March 7, 2019Publication date: July 4, 2019Applicant: The University of SheffieldInventor: Jonathan Raffe Willmott
-
Patent number: 10280197Abstract: A method of selectively modulating the activity of C5a receptor 2 (C5aR2). The method includes exposing the receptor to a compound that selectively modulates C5aR2 compared to C5a receptor 1 (C5aR1). In some cases, the compound is peptide P32 or P59. Methods of recruiting ?-arrestin 2 in a cell, modulating C5a-induced ERK1/2 activation in a macrophage, selectively inhibiting the release of IL-6 from a macrophage, are also provided.Type: GrantFiled: October 17, 2016Date of Patent: May 7, 2019Assignees: The Regents of the University of California, The Texas A & M University System, The University of Queensland, The University of SheffieldInventors: Dimitrios Monikis, Christodoulos Floudas, Trent Woodruff, Matthew A. Cooper, Daniel E. Croker, Peter N. Monk
-
Patent number: 10227680Abstract: A first multi phase niobium silicide alloy composition consists essentially of: from 15 to 24 at % of Si; from 0 to 25 at % of one or more sp outer electron configuration element which is not Si; from 1 to 26 at % of one or more sd outer electron configuration element which is not Nb; and a balance of Nb, interstitials and impurities. This alloy may be used to increase the creep resistance of an article, for example a gas turbine engine blade. A second multi phase niobium silicide alloy composition consists essentially of: from 1 to 24 at % of Si; from 0 to 34 at % of one or more sp outer electron configuration element which is not Si; from 19.5 to 48.5 at % of one or more sd outer electron configuration element which is not Nb or Cr; from 0.5 to 9 at % Cr; and a balance of Nb, interstitials and impurities. This alloy may be used to increase the creep resistance and/or to increase the oxidation resistance of an article, for example a gas turbine engine blade.Type: GrantFiled: June 17, 2009Date of Patent: March 12, 2019Assignee: The University of SheffieldInventor: Panos Tsakiropoulos
-
Patent number: 10150946Abstract: The present invention relates to a medium for storing, preserving, culturing, and/or differentiating stem cells. The medium employs a synthetic thermo-responsive copolymer, dispersed in an aqueous vehicle, which allows the medium to be readily “switched” between a non-gelatinous (fluid) form and a gelatinous form by simply adjusting temperature across the gelling temperature of the medium. As such, stem cells can be easily captured within a 3D gel matrix by simply mixing the stem cells with the non-gelatinous/fluid form of the medium and then gelling the medium by adjusting the temperature across the gelling temperature of the medium. The stem cells encapsulated within the gelatinous form of the medium may then be preserved for a significant time period before either using the stem cells directly within the medium (e.g. in therapy, or in culturing, differentiation, and such like), or after their extraction from the medium.Type: GrantFiled: February 21, 2014Date of Patent: December 11, 2018Assignee: The University of SheffieldInventors: Irene Canton, Steven Peter Armes, Nicholas John Warren, Harry Moore, Giuseppe Battaglia, Denis Cecchin
-
Patent number: 10128709Abstract: An electric machine comprising: a) a first means for providing a first magneto motive force comprising a first set of magneto motive force space harmonics comprising odd and even harmonic subsets, each harmonic in said first set of magneto motive force space harmonics having a respective amplitude, wherein one of said odd or even subsets of said first set of magneto motive force space harmonics comprises a dominant working harmonic and the other of said odd or even subsets of said first set of magneto motive force space harmonics comprises a dominant undesirable harmonic; and b) a second means for providing a second magneto motive force comprising a second set of magneto motive force space harmonics comprising odd and even harmonic subsets, each harmonic of said second set of magneto motive force space harmonics having a respective amplitude, wherein one of said odd or even subset of said second set of magneto motive force space harmonics comprises a dominant working harmonic and the other of said odd or eType: GrantFiled: November 29, 2013Date of Patent: November 13, 2018Assignee: The University of SheffieldInventor: Jiabin Wang
-
Publication number: 20170271846Abstract: A laser structure comprising a first photonic crystal surface emitting laser (PCSEL), a second PCSEL, and a coupling region that extends between the first PCSEL and the second PCSEL along a longitudinal axis and that is electrically controllable so as to be capable of coherently coupling the first PCSEL to the second PCSEL. Each PCSEL include an active layer, a photonic crystal, and a two-dimensional periodic array distributed in an array plane parallel to the longitudinal axis within the photonic crystal where the two-dimensional periodic array is formed of regions having a refractive index that is different to the surrounding photonic crystal.Type: ApplicationFiled: August 21, 2015Publication date: September 21, 2017Applicant: The University of SheffieldInventors: Richard James Edward Taylor, David T. D. Childs, Richard Hogg